Related News2019-02-15T06:42:55-06:00

Related News

Percentage of Pets Covered By Insurance Continues to Grow

One in four dogs will be diagnosed with cancer in their lifetimes, and that’s only one of many diseases that can present a pet owner with a difficult health decision for their pet. This article highlights that an increasing number of pet owners are choosing to mitigate the financial challenges inherent in advanced treatments by purchasing pet insurance. According to Sarah A. Moser in a recent DVM360 article, the percentage of pets covered by insurance continues to grow, and looks to be accelerating with the millennial generation owning an ever increasing percent of total dogs and cats. Our inquiries indicate that ECI® [...]

January 15th, 2019|

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field [...]

October 25th, 2018|

ELIAS Autologous Prescription Product Exceeds Expectations for Trial Safety and Efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been [...]

July 31st, 2018|